AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9270508 — intervention group
Group type: EXPERIMENTAL
Intervention: Tretinoin emollient cream 0.05% applied three times weekly
Number of subjects: 126
Study 9270508 — intervention group
Group type: EXPERIMENTAL
Intervention: Tretinoin emollient cream 0.05% applied once weekly
Number of subjects: 126
Study 9270508 — intervention group
Group type: COMPARATOR
Intervention: No therapy
Number of subjects: 126
Study 7933724 — intervention group
Group type: EXPERIMENTAL
Intervention: Variable practice during intertrial intervals
Number of subjects: 80
Study 7933724 — intervention group
Group type: COMPARATOR
Intervention: Criterion task alone
Number of subjects: 80
Study 3474212 — intervention group
Group type: EXPERIMENTAL
Intervention: Ofloxacin
Number of subjects: 40
Study 3474212 — intervention group
Group type: COMPARATOR
Intervention: Cefazolin
Number of subjects: 40
Study 28845523 — intervention group
Group type: EXPERIMENTAL
Intervention: Dupilumab 300 mg weekly subcutaneous for 12 weeks
Number of subjects: 64
Study 28845523 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study 28845523 — intervention group
Group type: COMPARATOR
Intervention: Dupilumab vs. Placebo
Number of subjects: 64
Study 28845523 — intervention group
Group type: EXPERIMENTAL
Intervention: Dupilumab
Number of subjects: 64
Study 27029704 — intervention group
Group type: EXPERIMENTAL
Intervention: Palbociclib plus fulvestrant
Number of subjects: 521
Study 27029704 — intervention group
Group type: COMPARATOR
Intervention: Fulvestrant plus placebo
Number of subjects: 521
Study 24088635 — intervention group
Group type: EXPERIMENTAL
Intervention: Minimally invasive strabismus surgery (MISS)
Number of subjects: 14
Study 24088635 — intervention group
Group type: COMPARATOR
Intervention: Standard paralimbal strabismus surgery (SPSS)
Number of subjects: 14
Study 23430192 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glargine (GLA) at bedtime
Number of subjects: 75
Study 23430192 — intervention group
Group type: COMPARATOR
Intervention: Metformin (MET) 1,000 mg b.i.d.
Number of subjects: 75
Study 20507786 — intervention group
Group type: EXPERIMENTAL
Intervention: Sutures
Number of subjects: 156
Study 20507786 — intervention group
Group type: EXPERIMENTAL
Intervention: Human fibrin glue
Number of subjects: 156
Study 20507786 — intervention group
Group type: EXPERIMENTAL
Intervention: N-butyl-2-cyanoacrylate
Number of subjects: 156
Study 20507786 — intervention group
Group type: COMPARATOR
Intervention: Fibrin glue
Number of subjects: 156
Study 18256777 — intervention group
Group type: EXPERIMENTAL
Intervention: Tibolone 1.25 mg/day
Number of subjects: 308
Study 18256777 — intervention group
Group type: COMPARATOR
Intervention: Raloxifene 60 mg/day
Number of subjects: 308
Study 18256777 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 308
Study 16573256 — intervention group
Group type: EXPERIMENTAL
Intervention: MAS063DP cream
Number of subjects: 218
Study 16573256 — intervention group
Group type: COMPARATOR
Intervention: Vehicle cream
Number of subjects: 218
Study 12729864 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole (2 to 30 mg daily)
Number of subjects: 1549
Study 12729864 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Number of subjects: 1549
Study 12729864 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 1549
Study 10740336 — intervention group
Group type: EXPERIMENTAL
Intervention: Fish oil (Pikasol)
Number of subjects: 1579
Study 10740336 — intervention group
Group type: COMPARATOR
Intervention: Olive oil (control)
Number of subjects: 1579
Study 8638521 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrates
Number of subjects: 0
Study 8638521 — intervention group
Group type: COMPARATOR
Intervention: ACE inhibitors
Number of subjects: 0
Study 1490136 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational intervention to increase involvement of minority leaders in AIDS-related efforts
Number of subjects: 166
Study 1490136 — intervention group
Group type: COMPARATOR
Intervention: Religious leaders
Number of subjects: 166
Study 1490136 — intervention group
Group type: COMPARATOR
Intervention: Agency directors
Number of subjects: 166
Study 3815461 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefoxitin
Number of subjects: 91
Study 3815461 — intervention group
Group type: COMPARATOR
Intervention: Clindamycin-gentamicin
Number of subjects: 91
Study 30204483 — intervention group
Group type: EXPERIMENTAL
Intervention: Slow-Digesting, Low-Glycemic Load (SD-LGL) beverage (GL 730)
Number of subjects: 16
Study 30204483 — intervention group
Group type: COMPARATOR
Intervention: Isocaloric control beverage (GL 1124)
Number of subjects: 16
Study 30204483 — intervention group
Group type: COMPARATOR
Intervention: Habitual diet
Number of subjects: 16
Study 27257747 — intervention group
Group type: EXPERIMENTAL
Intervention: dCBT (n=135)
Number of subjects: 270
Study 27257747 — intervention group
Group type: COMPARATOR
Intervention: WL (n=135)
Number of subjects: 270
Study 24452791 — intervention group
Group type: EXPERIMENTAL
Intervention: ARCON (accelerated radiotherapy combined with carbogen breathing and nicotinamide)
Number of subjects: 345
Study 24452791 — intervention group
Group type: COMPARATOR
Intervention: Accelerated radiotherapy
Number of subjects: 345
Study 22409385 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous fibroblast therapy
Number of subjects: 372
Study 22409385 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 372
Study 20089463 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy body image program
Number of subjects: 421
Study 20089463 — intervention group
Group type: COMPARATOR
Intervention: Wait list control group
Number of subjects: 421
Study 18327364 — intervention group
Group type: EXPERIMENTAL
Intervention: Latanoprost 0.005% once daily
Number of subjects: 120
Study 18327364 — intervention group
Group type: COMPARATOR
Intervention: Dorzolamide 2% 3 times daily and Timolol 0.5% twice daily
Number of subjects: 120
Study 15771757 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursofalk suspension
Number of subjects: 24
Study 15771757 — intervention group
Group type: COMPARATOR
Intervention: Ursofalk capsules
Number of subjects: 24
Study 15771757 — intervention group
Group type: EXPERIMENTAL
Intervention: Ursofalk suspension and capsules
Number of subjects: 24
Study 12606917 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.2% ropivacaine 0.5 ml/kg with 2 microg/kg neostigmine
Number of subjects: 0
Study 12606917 — intervention group
Group type: COMPARATOR
Intervention: 0.2% ropivacaine 0.5 ml/kg
Number of subjects: 0
Study 10463904 — intervention group
Group type: EXPERIMENTAL
Intervention: Breast conserving techniques
Number of subjects: 0
Study 10463904 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant systemic treatments
Number of subjects: 0
Study 10463904 — intervention group
Group type: EXPERIMENTAL
Intervention: National breast screening programme
Number of subjects: 0
Study 8946504 — intervention group
Group type: EXPERIMENTAL
Intervention: 20-hour fast group
Number of subjects: 126
Study 8946504 — intervention group
Group type: COMPARATOR
Intervention: 26-hour fast group
Number of subjects: 126
Study 8946504 — intervention group
Group type: EXPERIMENTAL
Intervention: Celiac children in the 20-hour fast group
Number of subjects: 126
Study 8946504 — intervention group
Group type: EXPERIMENTAL
Intervention: IBS children in the 20-hour fast group
Number of subjects: 126
Study 1658138 — intervention group
Group type: EXPERIMENTAL
Intervention: UK 79300 100 mg every 12 h (group 2)
Number of subjects: 16
Study 1658138 — intervention group
Group type: EXPERIMENTAL
Intervention: UK 79300 25 mg every 12 h (group 1)
Number of subjects: 16
Study 1658138 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 6302937 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical application of Human-fibroblast-derived (Beta) interferon (Hu1FN-B) at a dosage of 2-5 x 10(5) reference units daily for one week.
Number of subjects: 0
Study 6302937 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical application of Human-fibroblast-derived (Beta) interferon (Hu1FN-B)
Number of subjects: 0
Study 6302937 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified treatment)
Number of subjects: 0
Study 31332918 — intervention group
Group type: EXPERIMENTAL
Intervention: H pylori infection
Number of subjects: 5558
Study 31332918 — intervention group
Group type: COMPARATOR
Intervention: Control (no H pylori infection)
Number of subjects: 5558
Study 29022084 — intervention group
Group type: EXPERIMENTAL
Intervention: trastuzumab emtansine (T-DM1)
Number of subjects: 0
Study 29022084 — intervention group
Group type: COMPARATOR
Intervention: capecitabine plus lapatinib (control)
Number of subjects: 0
Study 25730407 — intervention group
Group type: EXPERIMENTAL
Intervention: Grief-specific music therapy in addition to standard care
Number of subjects: 10
Study 25730407 — intervention group
Group type: COMPARATOR
Intervention: Standard care alone
Number of subjects: 10
Study 24304680 — intervention group
Group type: EXPERIMENTAL
Intervention: Very low-intensity (30% 1RM) knee extension exercise with continuous muscle contraction (LST)
Number of subjects: 18
Study 24304680 — intervention group
Group type: COMPARATOR
Intervention: Intermitted muscle contraction (CON)
Number of subjects: 18
Study 22292139 — intervention group
Group type: EXPERIMENTAL
Intervention: Tooth-clenching exercises at clenching levels of 10%, 20%, or 40% of maximal voluntary clenching.
Number of subjects: 41
Study 19308464 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous femoral nerve block
Number of subjects: 54
Study 19308464 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous femoral nerve block with additional continuous sciatic nerve block
Number of subjects: 54
Study 19308464 — intervention group
Group type: COMPARATOR
Intervention: Epidural analgesia
Number of subjects: 54
Study 17599335 — intervention group
Group type: EXPERIMENTAL
Intervention: Rupatadine 10 mg
Number of subjects: 20
Study 17599335 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydroxyzine 50 mg
Number of subjects: 20
Study 17599335 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 15204391 — intervention group
Group type: EXPERIMENTAL
Intervention: Desmopressin (0.4 mg)
Number of subjects: 66
Study 15204391 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticholinergic medication (5-10 mg)
Number of subjects: 66
Study 15204391 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination treatment (after 4 weeks of monotherapy)
Number of subjects: 66
Study 12362011 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone counseling sessions (up to seven sessions)
Number of subjects: 3282
Study 12362011 — intervention group
Group type: COMPARATOR
Intervention: Self-help materials + counseling (if called back)
Number of subjects: 3282
Study 12362011 — intervention group
Group type: EXPERIMENTAL
Intervention: Remaining subjects in treatment group (after factoring out counseling)
Number of subjects: 3282
Study 12362011 — intervention group
Group type: COMPARATOR
Intervention: Remaining subjects in control group (after factoring out counseling)
Number of subjects: 3282
Study 12362011 — intervention group
Group type: EXPERIMENTAL
Intervention: Those who made at least one attempt to quit in treatment group
Number of subjects: 3282
Study 12362011 — intervention group
Group type: COMPARATOR
Intervention: Those who made at least one attempt to quit in control group
Number of subjects: 3282
Study 11113067 — intervention group
Group type: EXPERIMENTAL
Intervention: rhuIL-10 8 microg/kg
Number of subjects: 329
Study 11113067 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 329
Study 11113067 — intervention group
Group type: EXPERIMENTAL
Intervention: rhuIL-10 1 microg
Number of subjects: 329
Study 11113067 — intervention group
Group type: EXPERIMENTAL
Intervention: rhuIL-10 4 microg
Number of subjects: 329
Study 11113067 — intervention group
Group type: EXPERIMENTAL
Intervention: rhuIL-10 8 microg
Number of subjects: 329
Study 11113067 — intervention group
Group type: EXPERIMENTAL
Intervention: rhuIL-10 20 microg
Number of subjects: 329
Study 8653830 — intervention group
Group type: EXPERIMENTAL
Intervention: Ascorbic acid (2 g)
Number of subjects: 46
Study 8653830 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 46
Study 1294345 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromergon (5 mg daily from cycle day 10 to onset of menstruation for two consecutive cycles)
Number of subjects: 21
Study 1294345 — intervention group
Group type: EXPERIMENTAL
Intervention: Bromergon
Number of subjects: 21
Study 1294345 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 21
Study 6375840 — intervention group
Group type: EXPERIMENTAL
Intervention: 3% acyclovir ointment
Number of subjects: 66
Study 6375840 — intervention group
Group type: COMPARATOR
Intervention: 3% vidarabine ointment
Number of subjects: 66
Study 6375840 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 66
Study 31013594 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 IU of RRR‐alpha‐tocopherol
Number of subjects: 79
Study 31013594 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 79
Study 30448886 — intervention group
Group type: EXPERIMENTAL
Intervention: 23G PPV
Number of subjects: 103
Study 30448886 — intervention group
Group type: COMPARATOR
Intervention: 20G PPV
Number of subjects: 103
Study 27604620 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunoadsorption (IA)
Number of subjects: 21
Study 27604620 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma exchange (PE)
Number of subjects: 21
Study 24885779 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-delivered positive imagery cognitive bias modification intervention
Number of subjects: 35
Study 24885779 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 35
Study 23061642 — intervention group
Group type: EXPERIMENTAL
Intervention: Automated self-management calls plus home blood pressure monitoring
Number of subjects: 200
Study 23061642 — intervention group
Group type: COMPARATOR
Intervention: Usual healthcare
Number of subjects: 200
Study 20499046 — intervention group
Group type: EXPERIMENTAL
Intervention: rosiglitazone 4 mg twice daily for 16 weeks
Number of subjects: 40
Study 20499046 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 40
Study 18340440 — intervention group
Group type: EXPERIMENTAL
Intervention: Local anesthetic administered to the vocal folds
Number of subjects: 0
Study 18340440 — intervention group
Group type: COMPARATOR
Intervention: Normal kinesthesia (no anesthetic)
Number of subjects: 0
Study 15994610 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasonography followed by immediate surgical repair
Number of subjects: 752
Study 15994610 — intervention group
Group type: COMPARATOR
Intervention: Standard clinical examination (Control)
Number of subjects: 752
Study 12642973 — intervention group
Group type: EXPERIMENTAL
Intervention: 15-minute lecture intervention on completing a MedWatch form
Number of subjects: 78
Study 12642973 — intervention group
Group type: COMPARATOR
Intervention: Non-intervention (no lecture)
Number of subjects: 78
Study 10412782 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin, 20 mg/day
Number of subjects: 1200
Study 10412782 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1200
Study 8758152 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane anaesthesia
Number of subjects: 31
Study 1758242 — intervention group
Group type: EXPERIMENTAL
Intervention: N2O and isoflurane (Forane) discontinued simultaneously
Number of subjects: 24
Study 30066454 — intervention group
Group type: EXPERIMENTAL
Intervention: Incisional negative pressure wound therapy
Number of subjects: 876
Study 30066454 — intervention group
Group type: COMPARATOR
Intervention: Standard dressing
Number of subjects: 876
Study 30257282 — intervention group
Group type: EXPERIMENTAL
Intervention: Saphenous vein composite grafts
Number of subjects: 219
Study 30257282 — intervention group
Group type: COMPARATOR
Intervention: Right internal thoracic artery composite grafts
Number of subjects: 219
Study 30257282 — intervention group
Group type: EXPERIMENTAL
Intervention: Saphenous vein second limb conduits
Number of subjects: 219
Study 30257282 — intervention group
Group type: COMPARATOR
Intervention: Right internal thoracic artery second limb conduits
Number of subjects: 219
Study 30257282 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall survival
Number of subjects: 219
Study 30257282 — intervention group
Group type: EXPERIMENTAL
Intervention: Freedom from major adverse cardiac and cerebrovascular events
Number of subjects: 219
Study 27578305 — intervention group
Group type: COMPARATOR
Intervention: Ingenol mebutate gel (IMB) for 3 days
Number of subjects: 0
Study 27578305 — intervention group
Group type: EXPERIMENTAL
Intervention: Photodynamic therapy with methyl aminolevulinate (MAL-PDT) for a single session
Number of subjects: 0
Study 24316574 — intervention group
Group type: EXPERIMENTAL
Intervention: Satiety responsiveness
Number of subjects: 37
Study 24316574 — intervention group
Group type: EXPERIMENTAL
Intervention: Slowness in eating
Number of subjects: 37
Study 24316574 — intervention group
Group type: EXPERIMENTAL
Intervention: Food responsiveness
Number of subjects: 37
Study 24316574 — intervention group
Group type: EXPERIMENTAL
Intervention: Enjoyment of food
Number of subjects: 37
Study 24316574 — intervention group
Group type: EXPERIMENTAL
Intervention: Energy intake of snacks
Number of subjects: 37
Study 21402493 — intervention group
Group type: EXPERIMENTAL
Intervention: Motiva system (educational videos, motivational messages, and questionnaires)
Number of subjects: 97
Study 21402493 — intervention group
Group type: COMPARATOR
Intervention: Motiva system + telemonitoring of blood pressure, heart rate and weight
Number of subjects: 97
Study 20927422 — intervention group
Group type: EXPERIMENTAL
Intervention: Triclosan-containing mouthrinse and triclosan-containing dentifrice (group TT)
Number of subjects: 40
Study 20927422 — intervention group
Group type: COMPARATOR
Intervention: Control mouthrinse and triclosan-containing dentifrice (group CT)
Number of subjects: 40
Study 20927422 — intervention group
Group type: COMPARATOR
Intervention: Triclosan-containing mouthrinse and control dentifrice (group TC)
Number of subjects: 40
Study 20927422 — intervention group
Group type: COMPARATOR
Intervention: Control mouthrinse and control dentifrice (group CC)
Number of subjects: 40
Study 17513395 — intervention group
Group type: COMPARATOR
Intervention: Meal A (50 g complete amino acid mixture without extra arginine)
Number of subjects: 9
Study 17513395 — intervention group
Group type: EXPERIMENTAL
Intervention: Meal B (50 g complete amino acid mixture with 3 g extra arginine)
Number of subjects: 9
Study 15949921 — intervention group
Group type: EXPERIMENTAL
Intervention: Deramciclane 60 mg/day
Number of subjects: 208
Study 15949921 — intervention group
Group type: EXPERIMENTAL
Intervention: Deramciclane 30 mg/day
Number of subjects: 208
Study 15949921 — intervention group
Group type: EXPERIMENTAL
Intervention: Deramciclane 10 mg/day
Number of subjects: 208
Study 15949921 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 208
Study 12898851 — intervention group
Group type: EXPERIMENTAL
Intervention: Asymptomatic patients on CAPD with urinary tract infections (UTI)
Number of subjects: 43
Study 12898851 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetic patients on CAPD
Number of subjects: 43
Study 12898851 — intervention group
Group type: COMPARATOR
Intervention: Non-infected patients on CAPD
Number of subjects: 43
Study 10396388 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-operative assessment by a trained ophthalmic nurse at the peripheral clinic
Number of subjects: 49
Study 10396388 — intervention group
Group type: COMPARATOR
Intervention: Separate appointment for pre-operative assessment at the main hospital
Number of subjects: 49
Study 10396388 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-led pre-operative assessment
Number of subjects: 49
Study 10396388 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 49
Study 7552478 — intervention group
Group type: EXPERIMENTAL
Intervention: CD4‐IgG 30, 100, or 300 micrograms/kg weekly; 1,000 micrograms/kg once, twice, or three times per week; or 3,000 micrograms/kg twice weekly
Number of subjects: 22
Study 1705151 — intervention group
Group type: EXPERIMENTAL
Intervention: Citalopram
Number of subjects: 98
Study 1705151 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 98
Study 7040492 — intervention group
Group type: EXPERIMENTAL
Intervention: Bumetanide (1 to 10 mg/day)
Number of subjects: 43
Study 7040492 — intervention group
Group type: COMPARATOR
Intervention: Furosemide (40 to 400 mg/day)
Number of subjects: 43
Study 31003681 — intervention group
Group type: EXPERIMENTAL
Intervention: Gua Sha therapy (12 sessions, one session per week)
Number of subjects: 119
Study 31003681 — intervention group
Group type: EXPERIMENTAL
Intervention: Gua Sha therapy
Number of subjects: 119
Study 31003681 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 119
Study 27552000 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment based on TNF alpha inhibitors and low‐carbohydrates calorie‐restricted diet
Number of subjects: 20
Study 27552000 — intervention group
Group type: COMPARATOR
Intervention: TNF‐alpha inhibitors
Number of subjects: 20
Study 26686262 — intervention group
Group type: EXPERIMENTAL
Intervention: Text message reminders (daily tailored messages for 4 days)
Number of subjects: 92
Study 26686262 — intervention group
Group type: COMPARATOR
Intervention: Standard discharge instructions
Number of subjects: 92
Study 25300981 — intervention group
Group type: EXPERIMENTAL
Intervention: Kyphoplasty
Number of subjects: 404
Study 25300981 — intervention group
Group type: COMPARATOR
Intervention: Vertebroplasty
Number of subjects: 404
Study 21982723 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual testosterone 0.25 mg
Number of subjects: 16
Study 21982723 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual testosterone 0.50 mg
Number of subjects: 16
Study 21982723 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual testosterone 0.75 mg
Number of subjects: 16
Study 21982723 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual testosterone (all doses)
Number of subjects: 16
Study 19886836 — intervention group
Group type: EXPERIMENTAL
Intervention: Tenofovir/emtricitabine (TDF/FTC)
Number of subjects: 328
Study 19886836 — intervention group
Group type: COMPARATOR
Intervention: Control (single-dose nevirapine)
Number of subjects: 328
Study 16768082 — intervention group
Group type: EXPERIMENTAL
Intervention: Communication of the quality of life findings to the coordinating physician
Number of subjects: 200